Skip to main content

Newsroom press releases

01/12/22 - 18:30

2023 Annual Calendar of Corporate Events (288 KB)
Other
Download

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
Products Molecular
Download

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
Products Molecular
Download

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
Financial Data
Download

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
Products Molecular
Download

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
Products Molecular
Download

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
Financial Data
Download

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
Products Immunodiagnostic
Download

07/06/22 - 18:06

Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
Other
Download

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
Products Molecular
Download

09/05/22 - 7:02

DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
Acquisition / Partnership
Download

06/05/22 - 17:33

Update 2022 Annual Calendar of Corporate Events (285.68 KB)
Financial Disclosures
Download

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
Financial Data
Download

02/05/22 - 12:55

Publication of the summary report of the votes cast (280.95 KB)
Financial Disclosures
Download

29/04/22 - 16:26

Shareholders' meeting 2022 (166.12 KB)
Other
Download

22/04/22 - 12:37

New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
Financial Disclosures
Download

13/04/22 - 16:43

DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
Financial Disclosures
Download

08/04/22 - 19:13

Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
Financial Disclosures
Download

08/04/22 - 9:53

Update annual calendar of corporate events 2022 (288.09 KB)
Financial Disclosures
Download

05/04/22 - 9:51

Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
Other
Download

04/04/22 - 18:12

Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
Other
Download

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
Financial Data
Download

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
Products Molecular
Download

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
Products Molecular
Download

29/12/20 - 18:22

DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance (400.67 KB)
Products Molecular
Download

17/12/20 - 17:57

DiaSorin - Policlinico San Matteo Hospital in Pavia vs. Technogenetics (298.96 KB)
Other
Download

07/12/20 - 10:35

Communication on total amount of voting rights (563.18 KB)
Other
Download

04/12/20 - 16:14

Form 3F (November 2020) (10.2 KB)
Other
Download

01/12/20 - 6:33

DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market (566.6 KB)
Products Immunodiagnostic
Download

11/11/20 - 12:41

North America growth drives up revenues and profitability in the first 9 months of 2020 (805.25 KB)
Financial Data
Download

26/10/20 - 18:30

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients (414.59 KB)
Products Immunodiagnostic
Download

23/10/20 - 19:41

Conclusion treasury shares buy-back plan (314.28 KB)
Other
Download

23/10/20 - 19:37

Weekly report treasury shares buy-back (436.92 KB)
Other
Download

16/10/20 - 18:28

Weekly report treasury shares buy-back (425.19 KB)
Other
Download

01/10/20 - 7:45

DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market (395.31 KB)
Products Immunodiagnostic
Download

01/10/20 - 7:32

DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market (488.09 KB)
Products Immunodiagnostic
Download

23/09/20 - 7:16

DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China (495.78 KB)
Acquisition / Partnership
Download

16/09/20 - 14:30

Update Annual Calendar of Corporate Events 2020 (222.26 KB)
Other
Download

16/09/20 - 7:25

DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens (477.67 KB)
Products Molecular
Download

08/09/20 - 7:31

DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution (506.16 KB)
Acquisition / Partnership
Download

07/09/20 - 18:22

FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay (400.26 KB)
Products Molecular
Download

06/08/20 - 7:25

DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone (391.91 KB)
Products Immunodiagnostic
Download

31/07/20 - 16:04

Weekly report treasury shares buy-back (380.16 KB)
Other
Download

30/07/20 - 13:16

North America business growth drives Group revenues and profitability in H1 2020 (735.54 KB)
Financial Data
Download

24/07/20 - 17:19

Weekly report treasury shares buy-back (363.73 KB)
Other
Download

17/07/20 - 18:19

Weekly report treasury shares buy-back (360.09 KB)
Other
Download

10/07/20 - 18:23

Weekly report treasury shares buy-back (374 KB)
Other
Download

09/07/20 - 7:27

DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study (399.63 KB)
Products Immunodiagnostic
Download

07/07/20 - 7:22

DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay (490.1 KB)
Products Molecular
Download

30/06/20 - 7:25

DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients (397.37 KB)
Products Immunodiagnostic
Download

19/06/20 - 17:20

Weekly report treasury shares buy-back (399.38 KB)
Other
Download

17/06/20 - 16:09

Start up of the treasury shares buy-back plan (481.28 KB)
Other
Download

12/06/20 - 7:30

DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay (478.6 KB)
Products Molecular
Download

10/06/20 - 15:40

Shareholders' Meeting June 10, 2020 (308.25 KB)
Other
Download

03/06/20 - 14:16

The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA (397.21 KB)
Products Immunodiagnostic
Download

02/06/20 - 14:58

Communication total amount voting rights (record date) (267.83 KB)
Download

18/05/20 - 11:28

The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada (308.26 KB)
Products Immunodiagnostic
Download

13/05/20 - 13:15

DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic (741.65 KB)
Financial Data
Download

25/04/20 - 16:49

DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG (403.66 KB)
Products Immunodiagnostic
Download

17/04/20 - 18:25

DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19 (464.49 KB)
Products Immunodiagnostic
Download

07/04/20 - 7:14

IgG test to detect immune response to SARS-CoV-2 (394.92 KB)
Products Immunodiagnostic
Download

26/03/20 - 18:14

Update Annual Calendar of Corporate Events 2020 (277.25 KB)
Other
Download

21/03/20 - 20:29

Shareholders' Meeting date change (288.23 KB)
Other
Download

20/03/20 - 7:28

DiaSorin COVID-19 test has received FDA Emergency Use Authorization (397.04 KB)
Products Molecular
Download

13/03/20 - 17:16

DiaSorin received BARDA funding to develop a rapid COVID-19 test (403.34 KB)
Products Molecular
Download

11/03/20 - 13:43

DiaSorin - Cash flow generation and net profit hit record highs in 2019 (919.6 KB)
Financial Data
Download

10/03/20 - 8:20

DiaSorin - Development of Coronavirus test (404.03 KB)
Products Molecular
Download

02/03/20 - 8:04

DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology (396.06 KB)
Acquisition / Partnership
Download

07/02/20 - 8:06

Communication on total amount of voting rights (281.13 KB)
Other
Download

15/01/20 - 16:51

Annual Calendar of Corporate Events 2020 (124.73 KB)
Other
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.